Vyndamax Capsule, Liquid Filled
Product Images NDC 0069-8730

This is a graph showing the percentage of patients who had a worse or better status in relation to the KCCQ-Overall Summary Score. It indicates that the study had 84 patients in the placebo group and 170 patients in the pooled VYNDAQEL group, but without further information given, it is unclear what the study was about.*

This appears to be a table of data comparing the drug VYNDAQEL to a placebo for patients with two different TTR genotypes and varying NYHA classes and doses. The table includes percentages of patients in each category as well as statistical measures such as hazard ratios and risk ratios for all-cause mortality and cardiovascular hospitalization frequency. The F-S method is also mentioned but is not explained further.*

This is a description of the distributor of a product called Pfizer Labs. It is a division of Pfizer Inc, based in NY, NY 10017.*

This text provides information about the distributor of Pfizer Labs, a division of Pfizer Inc., located in New York, NY 10017.*

Vyndager ECTRTEEreY is a medication in capsule form that contains 20mg tafamidis meglumine, equivalent to 12.2mg tafamids, with a recommended daily dosage of 80mg (four capsules). It is important to note that Vyndagel is not substitutable on a per mg basis with other tafamidis products. The medication should be stored between 21°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). Each carton contains three blister cards with ten capsules in each card, for a total of thirty capsules per carton. The medication is not for individual resale and is distributed by Pfizer Labs, a division of Pfizer Inc in New York City.*

The text seems to be describing a medication called "Vyndaqer EXTRRRg" (tafamidis meglumine capsules). The medication comes in cartons and each carton contains 120 capsules, divided into four intermediary cartons, three blister cards per intermediary carton, and each blister card contains ten capsules. The capsules contain 20 mg of tafamidis meglumine. The text notes that Vyndaqel is not interchangeable on a per mg basis with other tafamidis products. The medication should be stored in room temperature, between 20 to 27 °F or 77 °F and excursions permitted up to 150 035 G5 Lo 56F. The text also provides the manufacturer's location but does not include any instructions for use.*

This appears to be a list of different forms and manufacturers of Vyndamax capsules, which contain the drug tafamidis. Each capsule contains 61mg of the drug. Some of the manufacturers listed include PlerLabs, PhaerLabs, and PizerLabs. The document also includes product codes and identification numbers for the capsules.*

Vyndamae (tafamidis) capsules are a prescription medication, available in a carton containing three blister cards which hold ten capsules each, for a total of 30 capsules. The capsule's NDC is 0069-8730-30. Pharmacists should note that Vyndamax is not interchangeable on a per mg basis with tafamidis meglumine packets. No additional information is available due to the minimal text.*